DermTech Inc : DMTK

DMTK

Stock Data

$0.00

$0.00 (0.00%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

DermTech, Inc., a molecular diagnostics company, develops and markets new non-invasive genomic tests to diagnose skin cancer, inflammatory diseases, and age-related conditions in the United States. The company is headquartered in La Jolla, California.

All DMTK Articles

2 Articles

Lee Jackson | Jul 19, 2022 at 8:53 AM EDT

Tuesday’s Top Analyst Upgrades and Downgrades: Alphabet, Chipotle, Exxon, Goodyear, Paramount, Teladoc, Tesla and More

Tuesday's top analyst upgrades and downgrades included Alphabet, Arista Networks, BorgWarner, Chipotle Mexican Grill, Exxon Mobil, Goodyear Tire & Rubber,…

Chris Lange | Jul 13, 2021 at 8:05 AM EDT

Why Jim Cramer Has Such a Positive Outlook for the Rest of 2021

24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.

DermTech Inc : DMTK

DMTK

$0.00

All DMTK Articles

Tuesday’s Top Analyst Upgrades and Downgrades: Alphabet, Chipotle, Exxon, Goodyear, Paramount, Teladoc, Tesla and More

Why Jim Cramer Has Such a Positive Outlook for the Rest of 2021

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Warren Buffett’s Parting Gift to Investors Is Crushing the Market 6 Months Later

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

College-Educated Families Earned $242,200 While Others Made $42,200, Here's Why the Gap Widened

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

DermTech Inc : DMTK

DMTK

$0.00

All DMTK Articles

Tuesday’s Top Analyst Upgrades and Downgrades: Alphabet, Chipotle, Exxon, Goodyear, Paramount, Teladoc, Tesla and More

Why Jim Cramer Has Such a Positive Outlook for the Rest of 2021

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Warren Buffett’s Parting Gift to Investors Is Crushing the Market 6 Months Later

Featured Reads

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

College-Educated Families Earned $242,200 While Others Made $42,200, Here's Why the Gap Widened